Study of Matuzumab with Chemotherapy for Oesophagogastric Cancer
Author Information
Author(s): Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A
Primary Institution: Royal Marsden Hospital, Surrey, UK
Hypothesis
To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of matuzumab combined with ECX in patients with advanced oesophagogastric cancer expressing EGFR.
Conclusion
The study found that matuzumab combined with ECX was well-tolerated and showed promising antitumor activity in patients with advanced oesophagogastric cancer.
Supporting Evidence
- The maximum tolerated dose of matuzumab was determined to be 800 mg weekly.
- The overall objective response rate was 65%, with 25% of patients achieving disease stabilization.
- Common toxicities included rash, nausea, stomatitis, and diarrhea.
Takeaway
This study tested a new treatment for stomach cancer and found it to be safe and effective for many patients.
Methodology
This was a phase I dose escalation study where patients received matuzumab combined with ECX until disease progression or unacceptable toxicity.
Limitations
The study had a small sample size and was not primarily designed to evaluate efficacy.
Participant Demographics
{"gender":{"male":16,"female":5},"age":{"median":59},"karnofsky_performance_status":{"60":1,"70":2,"80":5,"90":13},"primary_tumor_location":{"lower_one_third_of_oesophagus":5,"OGJ":7,"gastric":9},"stage":{"IIIb":1,"IV":20}}
Statistical Information
Confidence Interval
{"objective_response_rate":"65% (95% CI: 43–82)","disease_stabilization":"25% (95% CI: 11–47)"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website